NCT03650881

Brief Summary

This is a single-center prospective study of two standard-of-care treatments to evaluate the efficacy of the Neutrogena® Light Therapy Acne Mask an Over the Counter (OTC) Blue/Red light LED mask, as compared to the combination of topical OTC benzoyl peroxide 2.5% gel and OTC adapalene 0.1% gel, for the treatment of mild-to-moderate facial acne. This will be an investigator-blinded, randomized, 12-week study to observe these over the counter treatments. The two arms will be: (1) Neutrogena® Light Therapy Acne Mask (MASK), (2) topical OTC benzoyl peroxide 2.5% gel and OTC adapalene 0.1% gel (TOP). Both treatment groups in this study will also receive and use standardized, non-medicated cleansing and moisturizing products. All products will be purchased through commercial sources.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2018

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 7, 2018

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

August 27, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 29, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 5, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 5, 2020

Completed
Last Updated

May 20, 2020

Status Verified

May 1, 2020

Enrollment Period

1.5 years

First QC Date

August 27, 2018

Last Update Submit

May 18, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in the Investigator Global Assessment (IGA)

    5 point assessment tool used to measure inflammation caused by acne

    12 Weeks

Secondary Outcomes (1)

  • change in Acne Q4 quality of life index score

    12 Weeks

Study Arms (2)

Neutrogena ® Light Therapy Acne Mask (MASK)

EXPERIMENTAL

Over-the-counter powered light-based device for the treatment of acne

Drug: Neutrogena ® Light Therapy Acne Mask (MASK)

Topical benzoyl peroxide 2.5% gel and OTC adapalene

ACTIVE COMPARATOR

Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel

Drug: Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene

Interventions

Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes

Neutrogena ® Light Therapy Acne Mask (MASK)

Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night

Topical benzoyl peroxide 2.5% gel and OTC adapalene

Eligibility Criteria

Age12 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Diagnosis of acne vulgaris as determined by the study physician
  • Mild-to-moderate acne defined as a grade 2 or 3 on the FDA Investigator Global Acne Assessment (IGA) for Acne vulgaris (Appendix 1)19
  • If female,
  • Negative urine pregnancy test at the time of enrollment and negative urine pregnancy tests at follow up visits
  • Agreement to comply with medically acceptable forms of birth control with heterosexual intercourse
  • Agreement to comply with the study protocol and attend all study visits

You may not qualify if:

  • Is unwilling to participate in the survey
  • Outside of specified age range
  • Patients with clear, almost clear acne, or severe acne defined as grade 0-1 or 4 on the IGA Scale
  • Females who are pregnant or breastfeeding
  • Known allergy to any ingredients in the test products or history of photosensitivity
  • Pre-existing facial dermatologic conditions including excoriations that could interfere with the outcome of this study and quantification of acne lesions
  • Excessive facial hair or scarring that could interfere with quantification of acne lesions
  • Does not have decision making capacity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Gels

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

ColloidsComplex MixturesDosage FormsPharmaceutical Preparations
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 27, 2018

First Posted

August 29, 2018

Study Start

August 7, 2018

Primary Completion

February 5, 2020

Study Completion

February 5, 2020

Last Updated

May 20, 2020

Record last verified: 2020-05